|
|
|
|
| LEADER |
01882nam a2200241 a 4500 |
| 001 |
1761653 |
| 005 |
20171111234510.0 |
| 008 |
080709s2008 dcua sb 000 0 eng d |
| 020 |
|
|
|z 9780309116688
|
| 040 |
|
|
|a CaPaEBR
|z 0309116686
|
| 050 |
1 |
4 |
|a RC270.8
|b .I47 2008eb
|
| 245 |
0 |
0 |
|a Improving the quality of cancer clinical trials
|b workshop summary /
|c National Cancer Policy Forum, Margie Patlack and Sharyl Nass, rapporteurs.
|
| 260 |
|
|
|a Washington, D.C. :
|b National Academies Press,
|c c2008.
|
| 300 |
|
|
|a xii, 124 p. :
|b ill. (some col.).
|
| 504 |
|
|
|a Includes bibliographical references.
|
| 505 |
0 |
|
|a Introduction -- New clinical trial designs. Phase 0 trials -- Adaptive trial designs -- Targeting multiple pathways with multiple drugs -- Preclinical model systems -- Molecular imaging. Current and developing methods -- Challenges of molecular imaging -- Screening for predictive markers. The challenges of clinical validation -- Bioimaging predictive markers -- Clinical translation -- Panel discussion -- Costs of clinical trials. Regulatory costs -- Patient accrual -- Global outsourcing -- Time is money -- Public-private collaborations -- Regulatory issues. Regulatory barriers to innovation -- Patient advocacy perspective -- Regulation of in vitro diagnostics -- Regulatory issues in improving cancer clinical trials -- Reports from the case study discussion groups. Adaptive trial design -- Phase 0 trials -- Imaging -- Use of proteomics/genomics to assign therapy in lung cancer -- Use of genetics/genomics to assign therapy.
|
| 650 |
|
0 |
|a Cancer
|x Treatment
|z United States.
|
| 700 |
1 |
|
|a Patlak, Margie.
|
| 700 |
1 |
|
|a Nass, Sharyl J.
|
| 710 |
2 |
|
|a National Cancer Policy Forum (U.S.)
|
| 710 |
2 |
|
|a Institute of Medicine (U.S.)
|
| 856 |
4 |
0 |
|a ebrary, Inc.
|u http://site.ebrary.com/lib/ucy/Doc?id=10235163
|
| 952 |
|
|
|a CY-NiOUC
|b 5a0454086c5ad14ac1ec907f
|c 998a
|d 945l
|e -
|t 1
|x m
|z Books
|
